dc.contributor.author | Terwisscha van Scheltinga, SEJ | |
dc.contributor.author | Wijnen, MHWA | |
dc.contributor.author | Martelli, H | |
dc.contributor.author | Rogers, T | |
dc.contributor.author | Mandeville, H | |
dc.contributor.author | Gaze, MN | |
dc.contributor.author | McHugh, K | |
dc.contributor.author | Corradini, N | |
dc.contributor.author | Orbach, D | |
dc.contributor.author | Jenney, M | |
dc.contributor.author | Kelsey, A | |
dc.contributor.author | Chisholm, J | |
dc.contributor.author | Gallego, S | |
dc.contributor.author | Glosli, H | |
dc.contributor.author | Ferrari, A | |
dc.contributor.author | Zanetti, I | |
dc.contributor.author | De Salvo, GL | |
dc.contributor.author | Minard-Colin, V | |
dc.contributor.author | Bisogno, G | |
dc.contributor.author | van Noesel, MM | |
dc.contributor.author | Merks, HHM | |
dc.date.accessioned | 2021-12-07T09:27:06Z | |
dc.date.available | 2021-12-07T09:27:06Z | |
dc.identifier.citation | Cancer medicine, 2020, 9 (20), pp. 7580 - 7589 | |
dc.identifier.issn | 2045-7634 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4910 | |
dc.identifier.eissn | 2045-7634 | |
dc.identifier.doi | 10.1002/cam4.3365 | |
dc.description.abstract | Rhabdomyosarcoma of the extremities present with two main challenges: correct evaluation of initial regional nodal involvement and define adequate local treatment. Methods Pediatric patients with localized rhabdomyosarcoma of the extremity included in the EpSSG-RMS2005 study between 2005 and 2014 were evaluated for staging, treatment, and survival. The outcome was compared to the preceding European SIOP-MMT studies. Results Of the 162 patients included, histology was unfavorable in 113 (70%), 124 (77%) were younger than 10 years, 128 (79%) were IRS III, and 47 (29%) were node-positive. A regional node biopsy was performed in 97 patients (60%) and modified the lymph node stage in 15/97 (16%). Primary and delayed surgery was performed in 155 (96%) and radiotherapy delivered in 118 (73%) patients. Relapse occurred in 61 cases (38%), local in 14 (23%), regional in 13 (21%), distant in 22 (36%), and combined relapse in 12 (20%) with five progressive diseases (8%) and four secondary tumors (7%). Five-year event free (EFS) and overall survival (OS) were 58.4% (95%CI, 50.3-65.7) and 71.7% (63.6-78.4), respectively. In the previous studies MMT89 and MMT95, tumor surgery was performed in 32/53 (60%) and 74/82(90%), respectively, and radiotherapy delivered in 13/53 (25%) and 26/82 (30%), respectively. Five-year EFS and OS were 35.6%, and 50.3% in MMT89 and 54.3% and 68.2% in the MMT95 study. Conclusions Even if the lymph node staging was not always complete according to the RMS2005 protocol, node sampling changed lymph node status in a significant number of patients. Despite the higher rate of patients treated with locoregional radiotherapy, survival in RMS2005 did not improve compared to the previous European SIOP-MMT95 study. | |
dc.format | Print-Electronic | |
dc.format.extent | 7580 - 7589 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Extremities | |
dc.subject | Humans | |
dc.subject | Rhabdomyosarcoma | |
dc.subject | Neoplasm Metastasis | |
dc.subject | Recurrence | |
dc.subject | Diagnostic Imaging | |
dc.subject | Biopsy | |
dc.subject | Neoplasm Staging | |
dc.subject | Prognosis | |
dc.subject | Treatment Outcome | |
dc.subject | Combined Modality Therapy | |
dc.subject | Tumor Burden | |
dc.subject | Survival Analysis | |
dc.subject | Adolescent | |
dc.subject | Child | |
dc.subject | Child, Preschool | |
dc.subject | Infant | |
dc.subject | Disease Management | |
dc.subject | Female | |
dc.subject | Male | |
dc.subject | Clinical Decision-Making | |
dc.title | Local staging and treatment in extremity rhabdomyosarcoma. A report from the EpSSG-RMS2005 study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-07-20 | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1002/cam4.3365 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Cancer medicine | |
pubs.issue | 20 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials in Children and Young People | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials in Children and Young People/Sarcoma Clinical Trials in Children and Young People (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Clinical Trials in children and young people | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Clinical Trials in children and young people/Sarcoma Clinical Trials in Children and Young People (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Paediatric and Adolescent Radiotherapy | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 9 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Sarcoma Clinical Trials in children and young people | |
icr.researchteam | Paediatric and Adolescent Radiotherapy | |
dc.contributor.icrauthor | Mandeville, Henry | en_US |
dc.contributor.icrauthor | Chisholm, Julia | en_US |